(Q39674191)

English

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

scientific article published on July 28, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans (English)

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

0 references

author name string

Haizheng Hong

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hong Su

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Vikram Roongta

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Alban Allentoff

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Haojun Sun

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kevin Heller

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Tai Wong

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Steven Zhang

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Lisa J. Christopher

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

Blisse J. Vakkalagadda

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

Pamela L. Clemens

4

0000-0001-5562-9824

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

Christopher T. Harbison

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

Ramaswamy A. Iyer

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

William G. Humphreys

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20668249

12 June 2024

publication date

28 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

http://intl-dmd.aspetjournals.org/cgi/content/abstract/38/11/2049

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20668249

12 June 2024

https://syndication.highwire.org/content/doi/10.1124/dmd.110.034850

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Drug Metabolism and Disposition

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2049-2059

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

3

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.

4

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships

6

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Metabolism and disposition of dasatinib after oral administration to humans

7

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Limits for qualitative detection and quantitative determination. Application to radiochemistry

8

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

9

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.

10

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

11

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts

12

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a far

13

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

14

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs

15

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

16

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Current perspectives of 14 C-isotope measurement in biomedical accelerator mass spectrometry

0 references

Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.

18

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

19

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

20

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Erlotinib in previously treated non-small-cell lung cancer

21

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

22

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

23

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Lipid peroxide in the developing rat brain.

25

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

27

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Disposition of [1'-(14)C]stavudine after oral administration to humans

28

1 reference

10.1124/DMD.110.034850

https://api.crossref.org/works/10.1124/DMD.110.034850

12 June 2024

Identifiers

10.1124/DMD.110.034850

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39674191&oldid=2182493888"